34
FROM THE FACTORY
5 FACTORY DEVELOPMENTS Catalent breaks ground on new facility Catalent has broken ground on a new $112 million drug product manufacturing facility in Indiana. The site will increase the company’s fill/finish capacity in Bloomington and will house a range of technologies to support production. Catalent Biologics will create up to 200 new jobs to support the increased production. The new facility is expected to be completed by the end of 2024. Production of anti-cancer drugs boosted by new cleanroom Production of new anti-cancer drugs at ADC’s Bio North Wales manufacturing facility has been boosted by a new cleanroom, designed and built by WHP. The new facility supports the production of antibody drug conjugates through a stringently controlled environment, eliminating any risks during antibody modification and conjugation.
A key feature of the development by WHP was to install a bespoke low maintenance toxic waste system to remove cleanroom waste to a holding tank, where it is transported to an off-site incinerator. The system incorporates dry break couplers to seal off both ends of the pipeline to prevent the possibility of any onsite contamination. Wasdell commences operations in Dundalk The Wasdell Group has commenced operations at its EU headquarters after receiving its Manufacturer’s/Importation Authorisation licence (MIA) from the Health Products Regulatory Authority (HPRA). The new headquarters is located at the IDA Technology & Science Park in Dundalk, Ireland and is thought to be the fastest custom-built site to achieve cGMP approval. Vincent Dunne, CEO said: “This is another significant
milestone for Wasdell, and I am extremely proud of our team and the efforts made to open this facility.” GSK dedicated to Singapore to advance technologies GSK has opened a new $130 million manufacturing facility in Jurong as part of a company roadmap dedicated to developing advanced technologies in Singapore. The investment comes as part of the GSK-Economic Development Board 10-year Singapore Manufacturing Roadmap. GSK has expanded one of the production buildings on its Jurong site in an effort to accelerate the supply of new medicines to patients. Mr Chng Kai Fong, managing director, Singapore Economic Development Board said: “Over the years, GSK has continually partnered with Singapore to develop advanced manufacturing technologies, such as continuous manufacturing
and digital manufacturing. They have also been a strong partner in training our local talent. These efforts have supported the growth of the industry as a whole and in turn has created diverse and attractive job opportunities for Singapore.” Onyx Scientific to expand UK facility Onyx Scientific has strategically invested in its UK facility to position the company for a commercial API license. The investment is driven by a growing demand for flexible, specialist and small-scale API manufacture. The company will expand its UK facility to put in place the infrastructure to manage and commercialise customer projects. Onyx is working with the Medicines and Healthcare Products Regulatory Agency (MHRA) and is expecting licence approval later this year.